CNS Pharmaceuticals, Inc. CNSP · Stock Open CNS Pharmaceuticals, Inc. in new tab
CNS Pharmaceuticals, Inc. Analysis (CNSP)
Is CNS Pharmaceuticals, Inc. a good investment? CNS Pharmaceuticals, Inc. (CNSP) is currently trading at 5.22 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that CNS Pharmaceuticals, Inc. is undervalued compared to historical market norms.
Earnings Schedule: CNS Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -0.39.
Investor FAQ
Does CNS Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is CNS Pharmaceuticals, Inc.?
CNS Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -15.39.
Company Profile
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 29, 2022 | 0.03 |
| June 5, 2024 | 1:50 |
| Feb. 21, 2025 | 1:50 |
| July 22, 2025 | 0.08 |
Community Discussion